[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Glucose Dependent Insulinotropic Receptor - Pipeline Review, H2 2019

December 2019 | 46 pages | ID: G2EA6438DF3EEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Glucose Dependent Insulinotropic Receptor - Pipeline Review, H2 2019

SUMMARY

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene. GPR119 is expressed at high concentrations in the pancreas and gastrointestinal tract. GPR119 regulates incretin and insulin hormone secretion. Activation of GPR119 receptor causes a reduction in food intake and weight gain. This target is a potential drug target in treatments for obesity and diabetes.

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 4, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Gastrointestinal which include indications Type 2 Diabetes, Obesity and Liver Diseases.

The latest report Glucose Dependent Insulinotropic Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
  • The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Overview
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development
Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Dong-A Socio Holdings Co Ltd
Hyundai Pharmaceutical Co Ltd
Japan Tobacco Inc
Kowa Co Ltd
Merck & Co Inc
Novartis AG
Scohia Pharma Inc
Taisho Pharmaceutical Holdings Co Ltd
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles
APD-597 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-1241 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTP-109192 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-2982 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCO-094 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Product Development Milestones
Featured News & Press Releases
Nov 04, 2010: Arena Pharmaceuticals Provides Update On GPR119 Portfolio For Type 2 Diabetes
Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round
Dec 15, 2008: Arena Pharmaceuticals Announces Initiation Of Phase I Clinical Trial Of Type 2 Diabetes Drug Candidate In Partnership With Ortho-McNeil-Janssen Pharmaceuticals
Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arena Pharmaceuticals Inc, H2 2019
Pipeline by CymaBay Therapeutics Inc, H2 2019
Pipeline by Dong-A Socio Holdings Co Ltd, H2 2019
Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2019
Pipeline by Japan Tobacco Inc, H2 2019
Pipeline by Kowa Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Scohia Pharma Inc, H2 2019
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Dong-A Socio Holdings Co Ltd
Hyundai Pharmaceutical Co Ltd
Japan Tobacco Inc
Kowa Co Ltd
Merck & Co Inc
Novartis AG
Scohia Pharma Inc
Taisho Pharmaceutical Holdings Co Ltd


More Publications